173 related articles for article (PubMed ID: 25295402)
1. Drug plan design incentives among Medicare prescription drug plans.
Huskamp HA; Keating NL; Dalton JB; Chernew ME; Newhouse JP
Am J Manag Care; 2014 Jul; 20(7):562. PubMed ID: 25295402
[TBL] [Abstract][Full Text] [Related]
2. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
[TBL] [Abstract][Full Text] [Related]
3. Medicare program; Medicare prescription drug benefit. Final rule.
Centers for Medicare & Medicaid Services (CMS), HHS
Fed Regist; 2005 Jan; 70(18):4193-585. PubMed ID: 15678603
[TBL] [Abstract][Full Text] [Related]
4. Comparison of statin adherence among beneficiaries in MA-PD plans versus PDPs.
Jung K; McBean AM; Kim JA
J Manag Care Pharm; 2012 Mar; 18(2):106-15. PubMed ID: 22380470
[TBL] [Abstract][Full Text] [Related]
5. Biosimilar formulary placement in Medicare Part D prescription drug plans: A case study of infliximab.
Socal MP; Ezebilo I; Bai G; Anderson GF
Am J Health Syst Pharm; 2021 Jan; 78(3):216-221. PubMed ID: 33289035
[TBL] [Abstract][Full Text] [Related]
6. Trends in Medicare Part D coverage of generics with equivalent brand-name drugs.
Dusetzina SB; Cubanski J; Roberts AW; Hoadley J; True S; Nshuti L; Neuman T
Am J Manag Care; 2021 Jul; 27(7):283-288. PubMed ID: 34314117
[TBL] [Abstract][Full Text] [Related]
7. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
[TBL] [Abstract][Full Text] [Related]
8. Variability of COPD inhaler coverage in Medicare Part D.
Wormser B; Socal MP; Anderson G
Am J Manag Care; 2021 May; 27(5):187-193. PubMed ID: 34002960
[TBL] [Abstract][Full Text] [Related]
9. In Medicare Part D plans, low or zero copays and other features to encourage the use of generic statins work, could save billions.
Hoadley JF; Merrell K; Hargrave E; Summer L
Health Aff (Millwood); 2012 Oct; 31(10):2266-75. PubMed ID: 23048108
[TBL] [Abstract][Full Text] [Related]
10. Geographic Variation in the Prevalence of High-Risk Medication Use Among Medicare Part D Beneficiaries by Hospital Referral Region.
Chinthammit C; Bhattacharjee S; Axon DR; Slack M; Bentley JP; Warholak TL; Wilson DL; Lo-Ciganic WH
J Manag Care Spec Pharm; 2020 Oct; 26(10):1309-1316. PubMed ID: 32996396
[TBL] [Abstract][Full Text] [Related]
11. Trends in the prescription drug plans delivering the Medicare Part D prescription drug benefit.
Brill JV
Am J Health Syst Pharm; 2007 Aug; 64(15 Suppl 10):S3-6; quiz S21-S23. PubMed ID: 17646551
[TBL] [Abstract][Full Text] [Related]
12. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
13. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
Yazdany J; Dudley RA; Chen R; Lin GA; Tseng CW
Arthritis Rheumatol; 2015 Jun; 67(6):1474-80. PubMed ID: 25900105
[TBL] [Abstract][Full Text] [Related]
14. Impact of multitiered copayments on the use and cost of prescription drugs among Medicare beneficiaries.
Gilman BH; Kautter J
Health Serv Res; 2008 Apr; 43(2):478-95. PubMed ID: 18370964
[TBL] [Abstract][Full Text] [Related]
15. Status report on Medicare Part D enrollment in 2006: analysis of plan-specific market share and coverage.
Cubanski J; Neuman P
Health Aff (Millwood); 2007; 26(1):w1-12. PubMed ID: 17118944
[TBL] [Abstract][Full Text] [Related]
16. Variation in estimated Medicare prescription drug plan costs and affordability for beneficiaries living in different states.
Davis MM; Patel MS; Halasyamani LK
J Gen Intern Med; 2007 Feb; 22(2):257-63. PubMed ID: 17356996
[TBL] [Abstract][Full Text] [Related]
17. Beneficiary price sensitivity in the Medicare prescription drug plan market.
Frakt AB; Pizer SD
Health Econ; 2010 Jan; 19(1):88-100. PubMed ID: 19191252
[TBL] [Abstract][Full Text] [Related]
18. Medicare Prescription Drug Plan Enrollees Report Less Positive Experiences Than Their Medicare Advantage Counterparts.
Elliott MN; Landon BE; Zaslavsky AM; Edwards C; Orr N; Beckett MK; Mallett J; Cleary PD
Health Aff (Millwood); 2016 Mar; 35(3):456-63. PubMed ID: 26953300
[TBL] [Abstract][Full Text] [Related]
19. Attribute substitution in early enrollment decisions into Medicare prescription drug plans.
Frakt AB; Pizer SD
Health Econ; 2008 Apr; 17(4):513-21. PubMed ID: 17935198
[TBL] [Abstract][Full Text] [Related]
20. Potential opportunity cost of neglecting to annually reassess Medicare Part D standalone prescription drug plan offerings: the price of contentment?
Walberg MP; Patel RA
J Am Pharm Assoc (2003); 2009; 49(6):777-82. PubMed ID: 19926558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
